Donitriptan (Pierre Fabre).
Pierre Fabre is developing donitriptan, a piperazide 5-HT1D agonist, as a potential treatment for migraine [175854]. In January 2001, donitriptan had completed phase I trials for migraine and was scheduled to enter phase II development [396027]. This compound has an increased potency and, importantly, markedly higher intrinsic activity in comparison to the well described tryptamine derivatives, naratriptan, zolmitriptan and sumatriptan [295769].
Dukat
M
M
Department of Medicinal Chemistry, School of Pharmacy, Medical College of Virginia Campus/Virginia Commonwealth University, Richmond 23298-0540, USA. mdukat@gems.vcu.edu
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy; D015394:Molecular Structure; D009570:Nitriles / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D010879:Piperazines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D017366:Serotonin Receptor Agonists / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D014363:Tryptamines
D015507:Drugs, Investigational; D009570:Nitriles; D010879:Piperazines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C120143:donitriptan